Obinutuzumab
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Obinutuzumab: From Chronic Lymphocytic Leukemia to Follicular Lymphoma
One-Sentence Summary
Obinutuzumab is a type II, glycoengineered anti-CD20 monoclonal antibody previously established in CD20-positive B-cell malignancies such as chronic lymphocytic leukemia (CLL). The TxGNN model predicts strong efficacy for Follicular Lymphoma, and unlike most model-only predictions this one is already backed by 50 clinical trials (including the pivotal Phase 3 GALLIUM study) and 20 publications identified in this evidence pack.
Note: this evidence pack contains three TxGNN-predicted indications for obinutuzumab. Two additional predictions — CLL/SLL with IGHV somatic hypermutation, and pregerminal-center CLL/SLL — returned zero matching trials or literature (Evidence Level L5, decision stage S0, recommendation Hold) and are not discussed further below.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic Lymphocytic Leukemia (CLL) — per clinical trial evidence (NCT02877550); no Taiwan/NZ license record available to confirm formally |
| Predicted New Indication | Follicular Lymphoma |
| TxGNN Prediction Score | 99.18% |
| Evidence Level | L1 |
| New Zealand Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Obinutuzumab is a second-generation, glycoengineered, type II anti-CD20 monoclonal antibody. Compared with first-generation anti-CD20 agents (e.g., rituximab), its glycoengineered Fc region enhances antibody-dependent cellular cytotoxicity (ADCC) and direct B-cell killing, in addition to complement-dependent cytotoxicity (CDC).
CD20 is stably and highly expressed on malignant B cells in both CLL and follicular lymphoma (FL), so the drug's core mechanism transfers directly across these indications. This is not a purely speculative prediction: obinutuzumab already carries a regulatory-grade evidence base in FL — the Phase 3 GALLIUM trial (NCT01332968, n=1,401) demonstrated superior progression-free survival for obinutuzumab-based versus rituximab-based immunochemotherapy in previously untreated advanced FL, and this has been corroborated by multiple follow-on combination studies (with polatuzumab vedotin, venetoclax, lenalidomide, zanubrutinib, and others).
In short, the mechanistic rationale (shared CD20 target across CD20+ B-cell malignancies) and the clinical evidence base are mutually reinforcing, which is why this candidate reaches Evidence Level L1 rather than remaining a pure model prediction.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01332968 | Phase 3 | Completed | 1401 | GALLIUM: obinutuzumab + chemo vs rituximab + chemo in previously untreated advanced indolent NHL; pivotal trial supporting FL indication |
| NCT01059630 | Phase 3 | Completed | 413 | GADOLIN: bendamustine vs bendamustine + obinutuzumab in rituximab-refractory indolent NHL |
| NCT03817853 | Phase 4 | Completed | 114 | Post-marketing study of obinutuzumab short-duration (90-min) infusion safety in previously untreated advanced FL |
| NCT04034056 | N/A (non-interventional) | Completed | 299 | Real-world effectiveness/safety of obinutuzumab in previously untreated advanced FL, relapse rate at 24 months |
| NCT03332017 | Phase 2 | Completed | 217 | ROSEWOOD: zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in relapsed/refractory FL |
| NCT02611323 | Phase 1/2 | Completed | 133 | Obinutuzumab + polatuzumab vedotin + venetoclax in relapsed/refractory FL |
| NCT03113422 | Phase 2 | Completed | 56 | Venetoclax + obinutuzumab + bendamustine as front-line therapy in high tumor burden FL |
| NCT02600897 | Phase 1/2 | Completed | 114 | Obinutuzumab + polatuzumab vedotin + lenalidomide in relapsed/refractory FL |
| NCT01582776 | Phase 1/2 | Completed | 317 | Obinutuzumab + lenalidomide in FL and relapsed/refractory aggressive B-cell lymphoma |
| NCT05783596 | Phase 2 | Active, not recruiting | 47 | Glofitamab + obinutuzumab as first-line treatment of FL and marginal zone lymphoma |
40 additional trials (mostly early-phase combination studies or currently recruiting) are on file but not shown here.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28976863 | 2017 | RCT | New England Journal of Medicine | Primary GALLIUM results: obinutuzumab-based vs rituximab-based chemotherapy in previously untreated advanced FL |
| 29856692 | 2018 | RCT | Journal of Clinical Oncology | GALLIUM sub-analysis: impact of chemotherapy backbone on efficacy/safety of obinutuzumab vs rituximab |
| 37506346 | 2023 | RCT | Journal of Clinical Oncology | ROSEWOOD: zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in relapsed/refractory FL |
| 31296423 | 2019 | RCT | The Lancet Haematology | GALEN: obinutuzumab + lenalidomide in relapsed/refractory FL |
| 37767550 | 2024 | RCT | Haematologica | Polatuzumab vedotin + bendamustine + rituximab or obinutuzumab in relapsed/refractory FL |
| 39830356 | 2024 | Review | Frontiers in Pharmacology | Rapid review of efficacy, safety, and cost-effectiveness of obinutuzumab in FL |
| 31360086 | 2017 | Review | Blood and Lymphatic Cancer: Targets and Therapy | Impact of obinutuzumab alone and in combination for FL |
| 38660754 | 2024 | Review | Turkish Journal of Haematology | Comprehensive review of FL management, including obinutuzumab-based regimens |
| 28276536 | 2016 | Review | Drugs of Today | Overview of obinutuzumab in FL |
| 35180337 | 2022 | Review | Oncology (Williston Park) | Current and emerging therapies in FL, including anti-CD20 antibodies |
10 additional publications are on file with pending classification.
New Zealand Market Information
No New Zealand authorization records are currently available — obinutuzumab is not marketed in New Zealand (未上市, 0 licenses on file). Market entry status will need to be confirmed directly with Medsafe.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy / Immunotherapy (glycoengineered anti-CD20 monoclonal antibody; not a conventional cytotoxic chemotherapeutic) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The follicular lymphoma prediction is supported by a pivotal completed Phase 3 RCT (GALLIUM) plus a large, consistent body of follow-on trials and literature (Evidence Level L1), giving this candidate a substantially stronger footing than a pure model prediction. However, obinutuzumab is not currently marketed in New Zealand, and drug-level safety and mechanism-of-action data remain unresolved (DG001: TFDA/Medsafe package insert — Blocking; DG002: MOA — High), so the candidate cannot yet clear a full safety pre-screen.
To proceed, the following is needed:
- Medsafe/TFDA package insert (warnings, contraindications, DDI) to resolve DG001 before safety pre-screening
- Structured drug mechanism-of-action data from DrugBank to resolve DG002
- Confirmation of New Zealand market entry pathway/status, since no local license currently exists
- Formal review of the two lower-confidence TxGNN predictions (CLL/SLL molecular subtypes) if those patient subpopulations become a priority — currently Hold, no supporting trials or literature identified
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.